Skip to content

Delcath Systems DCTH Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
Arcus Biosciences logo
Arcus BiosciencesRCUS

Other financials

Income statement

See full
Revenue$25.0M+26.3%
Gross profit$21.3M+25.5%
Operating income-$1.6M-355%
Net income-$1.1M-200%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$41.3M+223%
Total debt$907.0K-10.7%
Total equity$112.7M+40.5%
Total assets$124.8M+43.0%

Cash flow

See full
Operating cash flow$857.0K-61.1%
CapEx$570.0K+307%
Free cash flow$287.0K-86.1%

Valuation

See full
Market cap$425.31M-11.8%
Enterprise value$384.91M-18.2%
P/E120.6×
P/S4.7×-4.3×

Profitability

See full
Gross margin86%+1.1pp
Operating margin-118.1%-56.8pp
Net margin1.5%+0.8pp
FCF margin21.2%+15.2pp

Returns & leverage

See full
Return on equity1.9%+1.0pp
Debt / equity0.0×
Current ratio11.2×-4.7×

Where this comes from

Reported directly by Delcath Systems in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Delcath Systems’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Delcath Systems's cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Delcath Systems's cash and cash equivalents, end of period?
Delcath Systems (DCTH) reported cash and cash equivalents, end of period of $41.31M in Q1 2026.
How has Delcath Systems's cash and cash equivalents, end of period changed year-over-year?
Delcath Systems's cash and cash equivalents, end of period increased by 223.4% year-over-year, from $12.78M to $41.31M.
What is the long-term trend for Delcath Systems's cash and cash equivalents, end of period?
Over 5 years (2020 to 2025), Delcath Systems's cash and cash equivalents, end of period has grown at a 8.6% compound annual growth rate (CAGR), from $28.76M to $43.45M.